Metabolic dysfunction-associated steatotic liver disease (MASLD), including metabolic dysfunction-associated steatohepatitis (MASH) and its fibrotic and cirrhotic stages, poses a growing burden on healthcare globally [1]. The increasing prevalence and duration of obesity and type 2 diabetes mellitus (T2D) have led to a rapid increase in MASLD, which now affects an estimated 38% of the adult global population and up to 60–80% of individuals with elevated cardiometabolic risk [2,3]. Among patients with T2D in primary care, 5–10% already have MASLD-induced advanced fibrosis or cirrhosis [4], a key predictor of liver-related, cardiovascular, and all-cause mortality [5].
